8 Aug 2026
Tasmanian tiger de-extinction Colossal Biosciences a fraud, good idea or waste of money?
In this update, I breakdown the reality of modern thylacine de-extinction. While a corporate lab claims massive genetic advantages, I examine why these heavily funded projects could prove to be a complete waste of money compared to tracking active, surviving wild populations on the Australian mainland.https://www.sciencedirect.com/science... (https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rVGp1WTQ3UjJ4RTl3aXBxZHhaTEh1SHxBR3JiS2FsR0t5UXYzUDJfNXhCZ3Z2V25KQ0Q0UzVITGZjX2NMUml0UmtNUnNxWm1wMUZfRXlaUE9VQzVfM0ZjbkFNNDBrX3E4MG9jcS1wTVVlY1FJWk13ZFl1Y1NrcEt1cGNC&q=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS2213671125001092&v=IKdXOce4dlU)CommentaryEngineered proxies and the illusion of de-extinctionAuthor links open overlay panelDusko Ilic 1 21Department of Women and Children’s Health, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UKAvailable online 15 May 2025, Version of Record 10 June 2025SummaryThe recent creation of dire wolf-like canids by Colossal Biosciences marks a technical achievement in genome editing and synthetic embryology. But the project also demands a reevaluation of what we mean by “de-extinction”—and whether a phenotypic approximation constitutes species restoration.Colossal Biosciences (TX, USA; https://colossal.com/ (https://www.youtube.com/redirect?event=video_description&redir_token=QUM4Zm9rVFBPd0hWUEd6R1I5QUxIcFc3ejJHYnxBR3JiS2FraTVmOGJUVkdqOWJFZEktQ0JmaDNVTDdCLXcxamxkSGh2ZUtLLS1QTWtjX2xIeUhrdUZ5SU9tWkV5Q1MxNHdrMjYtbG12M3hXcWd2Tm5iNDdjVnhKaWlNYmxjUjB1&q=https%3A%2F%2Fcolossal.com%2F&v=IKdXOce4dlU)) announcement that it has successfully engineered and birthed three pups with phenotypic features reminiscent of the extinct dire wolf (Aenocyon dirus) has garnered significant attention. Using comparative genomics and multiplex CRISPR editing, researchers modified a gray wolf (Canis lupus) cell line to express twenty genetic edits across fourteen loci, informed by ∼91% of the reconstructed dire wolf genome. The resulting animals exhibit increased body mass, cranial robustness, and light coat pigmentation—traits consistent with the extinct species. But despite headlines declaring the dire wolf’s return, what has been achieved is not resurrection, but simulation: a synthetic proxy designed to mimic phenotype, not to replicate genotype.This distinction has profound implications for both the scientific and ethical framing of de-extinction. Genotype—the full genomic blueprint—is not simply a background variable. It encodes the developmental, behavioral, immunological, and ecological identity of a species. Phenotype, shaped by both genotype and environment, is its expression. In Colossal’s dire wolves, selected traits were prioritized for viability and recognizability, while potentially deleterious variants (e.g., pigmentation-associated mutations linked to sensory deficits) were excluded. The outcome is an engineered animal that resembles the dire wolf in form, but not in totality.Such work highlights the practical shift in de-extinction strategy from full genomic synthesis—still far beyond reach for mammalian genomes—to targeted phenotypic reconstruction. Instead, partial phenotypic fidelity—what Colossal’s team terms “functional de-extinction”—has become the operational endpoint: a pragmatic compromise that prioritizes outward resemblance and selected functional traits over complete genomic or ecological restoration.This raises essential questions for the field of synthetic biology. At what point does a heavily edited organism with partial trait recovery become a new species? How do we distinguish between de-extinction and de novo organism design? The dire wolf project also mirrors a growing commercial trend in synthetic biology: dual-use platforms that link scientific ambitions with monetizable applications. Colossal has positioned its work as ecologically restorative, yet its funding model, media strategy, and investor outreach (including celebrity partnerships and cinematic branding) signal an additional aim: to transform charismatic megafauna into biotech showcases and potential intellectual property assets. ConclusionColossal’s work advances genome editing and mammalian embryology in significant ways, and its technical achievements deserve recognition. But science progresses through clarity, not spectacle. As we build the tools to shape life with increasing precision, we must also build the conceptual frameworks to define what, exactly, we are creating.
